State of New Jersey Common Pension Fund D continued to hold its position in Charles River Laboratories International, Inc. (NYSE:CRL) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 35,000 shares of the medical research company’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D’s holdings in Charles River Laboratories International were worth $3,540,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRL. Vanguard Group Inc. raised its position in Charles River Laboratories International by 4.7% in the first quarter. Vanguard Group Inc. now owns 5,033,513 shares of the medical research company’s stock worth $452,764,000 after buying an additional 225,563 shares during the last quarter. BlackRock Inc. raised its position in Charles River Laboratories International by 12,573.1% in the first quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock worth $345,915,000 after buying an additional 3,815,298 shares during the period. FMR LLC raised its position in Charles River Laboratories International by 39.7% in the first quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock worth $223,806,000 after buying an additional 707,612 shares during the period. Ariel Investments LLC raised its position in Charles River Laboratories International by 30.7% in the first quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock worth $185,335,000 after buying an additional 483,564 shares during the period. Finally, State Street Corp raised its position in Charles River Laboratories International by 1.1% in the first quarter. State Street Corp now owns 1,239,943 shares of the medical research company’s stock worth $111,539,000 after buying an additional 13,759 shares during the period. 93.79% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International, Inc. (NYSE CRL) opened at 98.58 on Wednesday. Charles River Laboratories International, Inc. has a 52-week low of $67.20 and a 52-week high of $102.32. The company has a 50 day moving average price of $99.68 and a 200-day moving average price of $92.13. The firm has a market cap of $4.69 billion, a price-to-earnings ratio of 25.98 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to the consensus estimate of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The firm’s revenue was up 8.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.20 earnings per share. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a stock repurchase program on Wednesday, May 10th that allows the company to repurchase $150.00 million in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: “Charles River Laboratories International, Inc. (CRL) Stake Held by State of New Jersey Common Pension Fund D” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/16/charles-river-laboratories-international-inc-crl-stake-held-by-state-of-new-jersey-common-pension-fund-d.html.

CRL has been the subject of a number of recent analyst reports. Jefferies Group LLC reiterated a “buy” rating and issued a $106.00 price target on shares of Charles River Laboratories International in a research report on Friday, April 21st. Citigroup Inc. reiterated a “neutral” rating and issued a $104.00 price target (up previously from $90.00) on shares of Charles River Laboratories International in a research report on Thursday, May 11th. Barclays PLC set a $90.00 price target on Charles River Laboratories International and gave the company a “hold” rating in a research report on Saturday, May 13th. Credit Suisse Group reiterated a “neutral” rating and issued a $95.00 price target (up previously from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $96.94.

In other Charles River Laboratories International news, Director George Massaro sold 3,830 shares of the stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $100.81, for a total value of $386,102.30. Following the completion of the sale, the director now directly owns 18,731 shares in the company, valued at $1,888,272.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman James C. Foster sold 43,154 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total value of $4,315,400.00. Following the completion of the sale, the chairman now owns 361,178 shares of the company’s stock, valued at $36,117,800. The disclosure for this sale can be found here. Insiders sold 79,369 shares of company stock valued at $7,846,412 in the last quarter. 2.20% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.